Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Example Input: Paragraph: In late May, North Korea reported an outbreak of African swine fever (ASF) to the World Organisation for Animal Health (OIE), South Korea's agriculture ministry said but the North has not made any official comment on its outbreak. North Korea's Rodong Sinmun newspaper said on Wednesday nationwide preventive measures are being carried out to contain the virus, quoting North Korean leader Kim Jong Un as saying "prevention is the key to production in livestock industry". "Increasing livestock production goes hand in hand with raising farm animals safe from various diseases," said Kim according to the newspaper. "Once highly contagious diseases like African swine fever are spread .... herds of farm animals could die." Preventative measures include disinfecting farms and restricting sales of pork and processed meat, the newspaper said. North Korea raises mainly chicken, ducks and rabbits. Its pig population was 2.6 million as of 2017, according to data from Statistics Korea. In the wake of the North's outbreak, South Korea has stepped up disinfection measures near the shared border to keep the viral disease spreading to the South. So far, no further cases have been reported in North Korea. African swine fever (ASF) is fatal and highly contagious to pigs and wild boards, but it does not affect humans. Since the first outbreak of ASF in East Asia was reported in China in early August last year, the virus has spread across China including Vietnam. Claim: North Korea steps up measures to prevent spread of African swine fever.
Example Output: North Korea has stepped up measures to prevent the spread of the highly contagious and deadly African swine fever, its main state newspaper said on Wednesday, breaking its silence on the outbreak which was first reported in late May.

Example Input: Paragraph: "The story mentions that 30 capsules ofOSR#1 cost $60. It would have been nice had the story also includedinformation about the amount of active ingredient per capsuleand the manufacturer's recommendeddosage. This wouldhave allowed readers to make a better calculation as to the financial impact oftreatment. This is critical information consideringthese costs will be borne out of pocket by anyone usingOSR #1. The storyjuxtaposes a light-hearted""success story""with information about the industrial uses of OSR #1 for removing toxic heavy metals from contaminated soil. This is a clever way ofway of emphasizingthat the use of this product is based entirely on anecdote. The storyclearly states that there is no credible evidence supporting the efficacy of the product. The harms of this product are impossible to quantify, given that it doesn't seem to have been studied in humans or in animals. The story notes that otherchelating drugs carry ""significant risks""and ""can strip the body of metals necessary for health."" It would have been nice to see more specifics about what chelators can do, but the story satisfies the critierion. The story states that medical searches turned up no papers about OSR#1, and that the companywhich makesthe productprovided nopublished studies about its use. The story rightly suggests that this total lack of evidenceshould be deeply troubling. The story doesn't exaggerate the prevalence or severity of autism, or of the potentially toxic compounds sometimes used to treat it. The story quotes multiple experts on pharmacology and an FDA spokesperson. It also quotes from an interview with Boyd Haley, president of the company which makes OSR#1. It attempted to get a reaction from Kim Stagliano, an OSR #1 proponent, but this effort was not successful. While the story mentions that there other are chelation drugs out there, it could have mentioned that there areeducational strategies which can be helpful for children with autism and which have betterevidence to support their use. The story states that OSR#1 is, according to the manufacturer'swebsite, available onlythrough dentists' or doctors' offices. Itnotes, however,that theTribune was able to buy 30 capsules of the productdirectly from a compounding pharmacy listed on the site. We areimpressed that the Tribune went to these lengths toestablish the product's availability. The story provides a fairly detailedpedigree for OSR #1and discusses itssimilarity to other chelation therapiesused in the treatment of autism. It also gives credit to blogger Kathleen Seidel for being the first to raiseconcerns aboutOSR #1 in her blog, Neurodiversity.com The story is well sourced and is not based on a press release." Claim: Industrial chemical OSR#1 used as autism treatment
Example Output: "The product known as OSR #1 contains a chemical originally intended for clean-up of toxic waste at industrial sites. This story by the Chicago Tribune (which was republished by the Los Angeles Times) examineshow,despite a total lack of any researchon the product in humans,OSR#1 ended up being marketedas a ""dietary supplement"" for childrenwith autism. The story does an especially good job of pointing out the regulatory gaps whichcan allowrisky, poorly researchedproductsto be sold as ""cures"" to desperate parents and caregivers. It's an example of health journalism doing what it'ssupposed to do, and doing it well. Autism is a serious disorder which affects a growing number of children and their families and for which there are few goodtreatment options. Thisis asituation ripe for abuse by overzealous advocates andunscrupulous marketersof uNPRoven therapies. AsBoyd Haley, president of the company thatmake thethe OSR#1 supplement, puts it:""There are so many snake oil salesmen out there, it's just incredible."""

Example Input: Paragraph: "A one month supply of Lipozene can cost up to $90 as reported in this story. This article also pointed out that other companies sell similar supplementsfor a much lower cost. This story is clear and accurate in its overall message thatthere appear to be no weight-loss benefits from taking Lipozene. This story uses expert opinion to point out the severe diarrhea and gastrointestinal distress would be adverse effects of taking the very large doses of the glucomannan fiber in Lipozene that might help someone to lose weight. This story also noted that glucomannan is not FDA approvedas aweight-loss supplement. This authors of this story should be commended for their thorough research in medical literature and in consultation with independent experts to verify the lack of evidence supporting Lipozene's weight loss claims. The headline of this story ""Fiber-based Lipozene's weight-loss claims rest on thin evidence"" sums up the lack of credible evidence on whichLipozene bases its weight-loss claims. This story does a good job at pointing out that Lipozene's ""clinically proven"" ""fat-reducing power "" does not appear to be based on any data published in the medical literature. Perhaps this claim is based upon a small study reporting that individuals taking a fiber supplement similar to Lipozene on a very low calorie diet lost weight. Mathematically the amount of weight lost would be accounted for by diet alone. This story debunksLipozeneclaim that people can loseweight without dieting or exercisisngby citingcurrent medical opinion, and common sense. The story does point out that the Federal Trade Commission has taken legal action against the Obesity Research Institute for making false claims about its other gucomannan containing products. As a footnote,the Obesity Research Institutedoes not appear to conduct any research despite its ""lofty"" name. This story does not engage in disease mongering butclearly points out that themakers of Lipozene do. The parent company, Obesity Research Institute,capitalizeson thepublic's desire for a quick fix weight loss pill. This story took a well balanced approach to presenting both sides of the Lipozene story. Beneficial claims by the manufacturer were balanced with comments by two independent experts who expressed the opposite opinion. The story also tried unsuccessfully to verify claims that could not be otherwise verified with the manufacturer. The only significant omission ofthe story was notincluding basic information on weight-loss. Thisstory briefly mentions diet and exercise, but could more clearly state these are the proven ways to lose weight. Also, abrief sentence about gastric bypass surgeryin cases of severe obesity could have easily been included. There is no shortage of 'get thin quick products' being aggressively marketed in the media and widely available in drugstores trhoughout the country. Lipozene is no excpetion, as this story points out at the onset. This story makes it clear that weight-loss supplements including Lipozene are common place. We are confident the story did not rely on a news release." Claim: Fiber-based Lipozene's weight-loss claims rest on thin evidence
Example Output:
Lipozene, a weight-loss supplement containing a type of fiber called glucomannan, is being promoted as a magic bullet for weight loss. The evidence supporting this claim is weak at best as aptly indicated in this story's headline. This story was well researched and did agood jobevaluating and refutingLipozene's weight-loss claims based upon review of themedical literature and by interviews with independent experts. Lipozene'smanufacturer, the Obesity Research Institute, did not respond to requests for justification of these claims. As pointed out in this article, the Obesity Research Institutepaid a large settlement in response tothe Federal Trade Commission charge that they made false and misleadingclaims about two of its other products containing the same fiber compound as Lipozene. This story did a very good job of documenting its "bottom line" that despite aggressive marketing there is no evidence that Lipozene is a "weight-loss breakthorugh". This story is credible and was well done.